Welcome to our dedicated page for Soligenix SEC filings (Ticker: SNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Soligenix, Inc. (SNGX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing structured access to its 10-K and 10-Q reports, 8-K current reports and registration statements such as Form S-1. Soligenix describes itself in these documents as a Delaware-incorporated, late-stage biopharmaceutical company listed on The Nasdaq Capital Market, focused on rare-disease therapeutics and biodefense-oriented vaccines through its Specialized BioTherapeutics and Public Health Solutions segments.
For this issuer, Form 10-K and Form 10-Q are central for understanding segment results, research and development spending, risk factors and details on programs like HyBryte™ (SGX301) for cutaneous T-cell lymphoma, SGX302 for psoriasis, dusquetide-based candidates SGX942 and SGX945, and vaccine initiatives such as RiVax®, filovirus vaccines and CiVax™ leveraging the ThermoVax® platform. These periodic reports also describe government grant and contract funding from agencies including NIAID, DTRA and BARDA that support the Public Health Solutions segment.
Form 8-K current reports are particularly relevant for SNGX because they capture material events such as clinical milestones, FDA orphan drug designations, equity offerings and Nasdaq listing status updates. For example, 8-K filings in 2025 document an orphan drug designation for dusquetide in Behçet's Disease, a Nasdaq notice regarding stockholders’ equity compliance and a subsequent notice of regained compliance, the approval of a 2025 equity incentive plan, and the closing of a public offering that extended the company’s cash runway.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as new financing terms, changes in capital structure, or updates to clinical and regulatory strategy. Users can also track insider transaction reports on Form 4, along with registration statements like Form S-1 related to public offerings and warrant issuances, to better understand dilution, capital-raising activities and governance matters for Soligenix.
Soligenix, Inc. files a Post-Effective Amendment to its Form S-1 to update the prospectus and continue the registration of 5,330,560 Warrant Shares of common stock underlying previously issued warrants. The Offering Warrants exercise at $1.35 per share for five years. The prospectus states 10,306,079 shares outstanding prior to the offering and 15,636,639 shares if all Offering Warrants are exercised. The company discloses cash of $7.9 million as of December 31, 2025 and $5.9 million as of March 24, 2026, and notes a going concern with runway into the fourth quarter of 2026 absent additional financing.
Soligenix, Inc. amends its Form S-1 to register up to 1,054,688 shares of common stock issuable upon exercise of July 2024 warrants for resale by selling stockholders. The company will not receive proceeds from these resales.
As of March 24, 2026, there were 10,306,079 shares outstanding and the last reported Nasdaq sale price was $1.17. The filing incorporates the company’s Form 10-K for the year ended December 31, 2025 and discloses limited cash on hand, a going concern qualification, and an existing at-market equity sales agreement with potential remaining capacity.
Soligenix, Inc. amends its Form S-1 to register 4,253 shares of common stock (the “Warrant Shares”) issuable upon exercise of previously issued warrants. The prospectus states the Offering Warrants were initially exercisable at $6.40 per share; warrants to purchase 1,876 shares were amended in September 2025 to an exercise price of $1.35 and extended to September 25, 2029. The company reports 10,306,079 shares outstanding as of March 24, 2026. Assuming full exercise of the Offering Warrants, outstanding shares would increase to 10,310,332. The prospectus estimates net proceeds to the company of approximately $17,746 assuming full exercise. No selling stockholders are listed and no additional securities are being registered in this Amendment.
Soligenix, Inc. amends its Form S-1 to update the registration for 408,640 shares of common stock issuable upon exercise of previously issued warrants (the "Warrant Shares"). The prospectus states the Offering Warrants were originally exercisable at $24.00 and certain warrants (to purchase 105,501 shares) were amended in September 2025 to an exercise price of $1.35 with exercise extended to September 25, 2029. The company reports 10,306,079 shares outstanding pre-offering and a pro forma post-exercise figure of 10,714,719, and estimates net proceeds of approximately $7,417,762 assuming full exercise. The filing incorporates the Company’s audited results for the year ended December 31, 2025 and notes cash of $7.9 million as of that date and $5.9 million as of March 24, 2026, with a disclosed near-term funding need into late 2026.
Soligenix, Inc. filed its annual report detailing progress across its late-stage biopharmaceutical pipeline in rare diseases and public health. The company reports a non‑affiliate common stock market value of $4,590,609 based on the June 30, 2025 Nasdaq closing price and 10,306,079 common shares outstanding on March 24, 2026. Key programs include HyBryte™ for cutaneous T‑cell lymphoma, SGX302 for psoriasis, and dusquetide‑based candidates SGX945 and SGX942 for inflammatory and oncology‑related indications. The report highlights multiple regulatory designations, active Phase 3 and Phase 2a studies, new manufacturing partnerships, and long‑term patent protection for synthetic hypericin and vaccine platforms.
SOLIGENIX, INC. ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 4.99% equal to 529,731 shares of common stock as of 12/31/2025.
The filing states Armistice Capital is investment manager of the Master Fund, which is the direct holder, and that Armistice and Mr. Boyd exercise shared voting and dispositive power over the reported 529,731 shares. The Master Fund disclaims beneficial ownership due to the Investment Management Agreement.
Soligenix, Inc. filed a report highlighting a shareholder update letter from its CEO on pipeline progress, milestones, financing and cash runway. The company states it has sufficient capital to meet its goals through 2026 and continues to pursue strategic options, including partnerships and potential M&A.
Soligenix expects peak annual net sales of HyBryte™ in the U.S. to exceed $90 million, within a worldwide CTCL market estimated at more than $250 million annually. The worldwide psoriasis opportunity for SGX302 is estimated to exceed $1 billion annually, and SGX945 in Behçet's Disease about $200 million, supporting a total potential of roughly $2 billion in global annual sales.
The company reported approximately $10.5 million in cash as of the quarter ended September 30, 2025, plus about $500 thousand from New Jersey’s NOL sales program, and remains focused on completing the confirmatory Phase 3 HyBryte™ FLASH2 trial and advancing ex-U.S. partnership discussions.
Soligenix, Inc. is establishing an at-the-market stock offering of up to $3,450,000 of common stock under its existing shelf registration, using Rodman & Renshaw as sales agent. Shares may be sold from time to time on The Nasdaq Capital Market or other U.S. trading markets at market-related or negotiated prices, with Rodman earning up to 3.0% of the gross sales price as commission.
The company had 10,086,130 shares outstanding as of January 20, 2026, and provides an illustrative scenario of selling 2,500,000 shares at $1.38 per share, which would increase shares outstanding to 12,586,130. Net proceeds are intended to fund research and development, commercialization activities, and general corporate and working capital needs. Soligenix is a late-stage biopharmaceutical company focused on rare disease treatments, including its HyBryte photodynamic therapy program for cutaneous T‑cell lymphoma and several vaccine and biodefense candidates.